ArticleJournal of the American Board of Family Medicine : JABFM2025
Strengths and Weakness of the Atherosclerotic Cardiovascular Risk Calculation: A Qualitative Study.
Article in Journal of the American Board of Family Medicine : JABFM, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Coronary Plaque Burden in South Asian Adults: Insights From the DILWALE Registry.JACC. Advances · 2026Article
- Fifty Years From the First Framingham Risk Profile: Are We Getting Closer to Identifying and PREVENTing Subclinical Disease Progression?Journal of the American Heart Association · 2026Article
- The 4Cs of Primary Care, Leveraging Artificial Intelligence, and Improving Clinical Practice.Journal of the American Board of Family Medicine : JABFM · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPatients at risk of atherosclerotic cardiovascular disease (ASCVD) have low statin use. Clinician perceptions of the ASCVD risk estimates that guide statin prescribing may contribute to poor uptake. At the time of the study, the only equations used to predict ASCVD risk (the Pooled Cohort Equations; PCE) provided race-specific estimates, a controversial practice and a potential reason why clinicians may scrutinize these estimates. We sought to examine how clinicians perceived ASCVD estimates, in relation to their perceptions of race and, also, more broadly.
methodsWe conducted an interpretive description study using ten 45-minute semistructured interviews with primary care physicians in North Carolina between March and April 2022. Interviews focused on the PCE ASCVD risk calculator and perspectives of race as it relates to ASCVD. Responses were analyzed using both deductive and inductive approaches to identify primary topics.
results5 men and 5 women participated. Of these, 6 identified as White, 2 as Black, and 2 as Asian. Three main topics emerged. First, participants felt conflicted about the role of race in ASCVD risk. Second, they had several concerns with the calculator that went beyond race, including its emphasis on statin use and lack of social determinants of health. Finally, participants universally valued the PCE ASCVD calculator as a tool to educate patients and inspire statin initiation and behavioral change.
conclusionsThe PCE ASCVD risk calculator was seen as most useful in facilitating discussions regarding behavior and lifestyle changes, suggesting the potential benefit of incorporating variables related to patients' health behaviors in a revised model. The new PREVENT equations provide a helpful first step by removing race and including social determinants. The next step may be to add health behaviors and visual images to facilitate patient counseling and comprehension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.